

Resource Summary Report

Generated by T1D on Aug 2, 2026

Agilent: BioTek: Synergy LX Multi-Mode Microplate Reader

RRID:SCR_019763

Type: Tool

Proper Citation

Agilent: BioTek: Synergy LX Multi-Mode Microplate Reader (RRID:SCR_019763)

Resource Information

URL: <https://www.biotek.com/products/detection-multi-mode-microplate-readers/synergy-lx/>

Proper Citation: Agilent: BioTek: Synergy LX Multi-Mode Microplate Reader (RRID:SCR_019763)

Description: Microplate reader with an optic design that provides accurate data in absorbance, fluorescence and luminescence detection modes, enabling many common assays including nucleic acid and protein quantification, ELISA, BCA, Bradford and cell viability.

Resource Type: instrument resource

Keywords: Biotek, BioTek, Multi-Mode Microplate Reader, Instrument, Equipment,

Availability: Commercially available

Specification URL: https://raw.githubusercontent.com/SciCrunch/RRID-Instruments/refs/heads/main/PDF/SCR_019763.pdf

Resource Name: Agilent: BioTek: Synergy LX Multi-Mode Microplate Reader

Resource ID: SCR_019763

Alternate IDs: Model_Number_Synergy_LX

Record Creation Time: 20220129T080346+0000

Record Last Update: 20260801T190632+0000

Ratings and Alerts

No rating or validation information has been found for Agilent: BioTek: Synergy LX Multi-Mode Microplate Reader.

No alerts have been found for Agilent: BioTek: Synergy LX Multi-Mode Microplate Reader.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [T1D](#) .

Jolly JT, et al. (2025) Phosphatase activity is dispensable for PRL-3-mediated oncogenesis and tumor progression. bioRxiv : the preprint server for biology.

He Y, et al. (2025) Eph Receptors Activate Myeloid Checkpoint Receptor LILRB5 to Support Tumor Development. Cancer immunology research, 13(6), 821.

Ullah I, et al. (2023) The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. Cell reports. Medicine, 4(1), 100893.

Ullah I, et al. (2021) Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity, 54(9), 2143.